A clear commercialization push defines this week’s MedTech activity, as companies across neuromodulation, ultrasound therapy, and surgical devices advance through late-stage clinical programs and market entry. Complete updates follow below.
NVision raises $55M to expand from quantum MRI into quantum computing
The Series B funding round was led by Abbott, bringing NVision’s total funding to $120M.
The funding round includes a $17 million venture loan from the European Investment Bank and participation from existing investors including Playground Global, Entrée Capital, Matterwave and CDP Venture Capital.
Co-Founder and CEO Sella Brosh
Last week’s tracker: Senseonics, Sedivention & more
BlueWind Medical raises $47.8M to support Revi commercialization
The company plans to use the proceeds to fund further commercialization for its Revi neuromodulation system. Revi, an implantable tibial neuromodulation (ITNM) platform, treats urgency urinary incontinence (UUI).
According to BlueWind, proceeds should support expansion of its sales organization and ongoing investment in market access initiatives.
CEO Kerry Nelson
SonoMind raises $23.5M for focused ultrasound-based depression therapy
The company said the funding enables it to start clinical trials and collect evidence for its technology. It targets market authorization by 2029.
The Series A funding round was led by Critical Path Ventures and Bpifrance. It follows a $3.5M seed round completed last year.
CEO Jérémy Bercoff
Butterfly Medical raises $21M for BPH device
The Series C funding round supports its therapeutic approach and competitive positioning. The company now looks to pursue the FDA regulatory pathway and global commercialization.
New and existing investors contributed to the funding, including the European Innovation Council (EIC), Junson Capital, MedVenture and New Rhein Healthcare Investors.
CEO Patrick MacCarthy
Rivermark secures $20M in Series D for late-stage prostate device trial
Rivermark Medical has secured $20M in a Series D financing round, supporting the company’s late-stage clinical activities being used for approval of its flagship device for patients with an enlarged prostate.
With cash in hand from this capital raise, which was led by Andera Partners, the company will continue its pivotal RAPID III clinical study (NCT06849258) on its FloStent system.
Co-Founder and CEO Adam Kadlec
NinaMED raises $13.5M to support neuromod for overactive bladder
NinaMED announced its establishment as a medical device company with $13.5M raised in a financing led by SPRIM Global Investments.
The company plans to use the funds raised to accelerate the development of NiNA as it conducts clinical development efforts.
Chair of NinaMED Professor Ian Meredith
Urologic Health announces $11M Seed financing
The round was led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and additional healthcare-focused investors.
The funding will support the company’s clinical validation, FDA 510(k) regulatory pathway, and initial U.S. commercialization efforts.
Co-founder and CEOAdam Yaacov
Theraclion announces the strong success of its oversubscribed
Theraclion announces the strong success of its € 5,992,544.16 capital increase with preferential subscription rights, oversubscribed by investors, through the issuance of 12,484,467 New Shares with share subscription warrants at a unit price of € 0.48.
In addition, a total number of 12,484,467 BSA were issued, allowing the Company to raise, in the event of the exercise of all the BSA, an additional amount of € 1,997,514.72.
CEO Martin Deterre
NanoStruct raises €2.6M to bring AI-powered food safety testing to market
The company secured €2.6M in seed funding from High-Tech Gründerfonds (HTGF), Bayern Kapital, and the AUXXO Female Catalyst Fund to advance its rapid food safety testing technology.
The firm plans to validate its rapid food pathogen detection technology through pilot projects in the food analysis market, expand its team, build a structured sales organization, and accelerate the commercialization of its AI-powered nanostructured sensor chip platform.
CEO Henriette Maaß
Mobia Medical goes public with brain-stimulating stroke recovery device
Mobia Medical announced the pricing of its IPO of 10,000,000 shares of common stock at $15 per share.
With thefunding from Mobia Medical’s listing, the company will commercially expand in the US and raise awareness.
President and CEO Richard Foust
HealthQuad invests in LifeSigns to expand AI-based remote patient monitoring platform
HealthQuad has announced an investment in LifeSigns to support the expansion of its AI-powered remote patient monitoring platform across Southeast Asia and Gulf Cooperation Council (GCC) markets.
The investment will also be used to strengthen LifeSigns’ predictive care technology stack through selective AI integrations.
Co-Founders Hari Subramaniam, Shouri Akkineni, Dr. Girish Chandra
